XML 31 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Assets and Liabilities
3 Months Ended
Mar. 31, 2024
Fair Value of Financial Assets and Liabilities  
Fair Value of Financial Assets and Liabilities

6. Fair Value of Financial Assets and Liabilities

As of March 31, 2024 and December 31, 2023, the carrying amount of cash and cash equivalents and short-term investments was $201,199 and $275,846 respectively, which approximates fair value. Cash and cash equivalents and

short-term investments includes investments in U.S. treasury securities and money market funds that invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds and government funds are categorized as Level 1.  The financial assets valued based on Level 2 inputs consist of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations.

The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair value:

Fair Value Measurements as of

March 31, 2024 using:

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

Cash equivalents:

 

  

 

  

 

  

 

  

Money market funds

$

43,028

$

$

$

43,028

Marketable securities:

 

  

 

  

 

  

 

  

Corporate debt securities and commercial paper

147,771

147,771

Total

$

43,028

$

147,771

$

$

190,799

Liabilities:

 

  

 

  

 

  

 

  

Derivative liability

$

$

$

660

$

660

Total

$

$

$

660

$

660

Fair Value Measurements as of

December 31, 2023 using:

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

Cash equivalents:

 

  

 

  

 

  

 

  

Commercial paper

$

$

$

$

Money market funds

 

40,868

 

4,979

 

 

45,847

Marketable securities:

 

  

 

  

 

  

 

  

Corporate debt securities and commercial paper

215,765

215,765

Total

$

40,868

$

220,744

$

$

261,612

Liabilities:

Derivative liability

$

$

$

1,150

$

1,150

Total

$

$

$

1,150

$

1,150

The estimated fair value of the derivative liability related to our Royalty Interest Financing Agreement (RIFA) with HealthCare Royalty Partners was determined using Level 3 inputs. The fair value measurement of the derivative liability is sensitive to changes in the unobservable inputs used to value the financial instrument. Changes in the inputs could result in changes to the fair value of each financial instrument.

The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 12, “Long-Term Obligations”, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation on the condensed consolidated balance sheets. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of other (expense) income, net. The assumptions used in the option pricing Monte Carlo simulation model include: (1) our estimates of the probability and timing of related events; (2) the probability-weighted net sales of IMCIVREE, including worldwide net product sales, upfront payments, milestones and royalties; (3) our risk-adjusted discount rate that includes a company specific risk premium; (4) our cost of debt; (5) volatility; and (6) the probability of a change in control occurring during the term of the instrument.

Three months ended

March 31,

    

2024

    

2023

Beginning aggregate estimated fair value of Level 3 liabilities

$

1,150

$

1,340

Initial recording of embedded derivative

Change in fair value of embedded derivative

(490)

(50)

Ending aggregate estimated fair value of Level 3 liabilities

$

660

$

1,290

Marketable Securities

The following tables summarize the Company's marketable securities:

March 31, 2024

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

Assets

Corporate debt securities and commercial paper (due within 1 year)

$

147,742

$

51

$

(22)

$

147,771

$

147,742

$

51

$

(22)

$

147,771

December 31, 2023

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

Assets

Corporate debt securities and commercial paper (due within 1 year)

$

215,490

$

282

$

(7)

$

215,765

$

215,490

$

282

$

(7)

$

215,765